Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Illumina Stakes A Claim In NIPT Market With $450-Million Acquisition Of Verinata

Executive Summary

Gene-sequencing company Illumina has signed a definitive agreement to acquire Verinata Health for up to $450 million, staking its claim in the fast-growing, noninvasive prenatal genetic-testing market.


Related Content

2013: The Year In Diagnostics
Illumina’s Unique Leverage In NIPT
Device/Diagnostics Quarterly Deal Statistics, Q1 2013
Device Trends To Watch In 2013
Washington Roundup, February 2013
Molecular Diagnostics Ushers In New Era Of Prenatal Testing


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts